Amgen slams the brakes on a clutch of cancer drugs as reality BiTEs

Amgen is pausing and stopping a whole series of next-gen cancer assets as it tries to figure out the best way forward for its early oncology programs.

Buried in its annual financial results, released Tuesday night, is evidence the Big Pharma, which is hoping for success and approval with its closely watched KRAS hopeful sotorasib, is having a tougher time making its other next-gen assets work.